Altesa BioSciences, Inc.

COLLEGE PARK, GA · Founded 2020 · Biotech · Private

Therapeutic molecules targeting respiratory exacerbation mechanisms in COPD patients

Claim this profile

Follows are private to you and power your alerts

Updated · altesabio.com

Sector
Biotech
Headquarters
COLLEGE PARK, GA
Founded
2020
Latest Form D
$75M, Feb 2026
Total capital
$89.9M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$89.9M
2 Form D · last Feb 2026
8 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
0
25 pending

Capital timeline

2023202420252026FEDERAL ↑EQUITY ↓Cumulative $89.9M1st Form D$14.9M2nd Form D$75M
2023202420252026FEDERAL ↑EQUITY ↓Cumulative $89.9M1st Form D$14.9M2nd Form D$75M

Latest events

  • Private capital raisedForm D · SEC · 2nd filing$75M
  • Private capital raisedForm D · SEC · 1st filing$14.9M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Founders and team

From SEC Form D filings
  • Andrew DrechslerExecutive OfficerNamed in SEC Form D filings
  • Brett GiroirExecutive Officer, DirectorNamed in SEC Form D filings
  • Ittai HarelDirectorNamed in SEC Form D filings
  • John ClericiExecutive Officer, PromoterNamed in SEC Form D filings
  • Jon EdwardsDirectorNamed in SEC Form D filings
  • Moncef SlaouiDirectorNamed in SEC Form D filings
Show all 8 people
  • Nicholas WilliamsDirectorNamed in SEC Form D filings
  • Seth RudnickDirectorNamed in SEC Form D filings

What it has protected

USPTO · 0 granted of 25
  • PendingPharmaceutical Compositions And Methods Of Treating Enteroviruses With Vapendavir SulfateUSPTOApplication 19304285
  • PendingMethod Of Treating Hepatitis C Virus In PatientsUSPTOApplication 18672122
  • PendingMethod Of Dosing Vapendavir To Treat Enterovirus InfectionsUSPTOApplication 18604264
Show all 25 patent records
  • Pharmaceutical Compositions And Methods Of Treating Enteroviruses With Vapendavir SulfateFeb 19, 2026 · Application 19304285Pending
  • Method Of Treating Hepatitis C Virus In PatientsNov 28, 2024 · Application 18672122Pending
  • Method Of Dosing Vapendavir To Treat Enterovirus InfectionsOct 24, 2024 · Application 18604264Pending
  • Method Of Treating Enterovirus In Chronic Obstructive Pulmonary Disease PatientsSep 19, 2024 · Application 18604259Pending
  • Pharmaceutical Compositions And Methods Of Treating Enteroviruses With Vapendavir SulfateApplication 63804845Pending
  • Methods Of Treating Enterovirus In Asthma PatientsApplication 63743420Pending
  • Amorphous Form, Pharmaceutical Composition, And Method Of Treating EnterovirusesApplication 63715299Pending
  • Pharmaceutical Compositions And Methods Of Treating Enteroviruses With Vapendavir SulfateApplication 63715272Pending
  • Methods Of Treating Enterovirus In Asthma Patients With VapendavirApplication 63715323Pending
  • Salt Form, Pharmaceutical Composition, And Method Of Treating EnterovirusesApplication 63715172Pending
  • Salt Form, Pharmaceutical Composition, And Method Of Treating EnterovirusesApplication 63694305Pending
  • Method Of Treating Respiratory Conditions In Chronic Obstructive Pulmonary Disease PatientsApplication 63684661Pending
  • Salt Form, Pharmaceutical Composition, And Method Of Treating EnterovirusesApplication 63684652Pending
  • Amorphous Form, Pharmaceutical Composition, And Method Of Treating EnterovirusesApplication 63684655Pending
  • Method Of Treating Hepatitis C Virus In PatientsApplication PCTUS2024030697Pending
  • Method Of Dosing Vapendavir To Treat Enterovirus InfectionsApplication PCTUS2024019772Pending
  • Method Of Treating Enterovirus In Chronic Obstructive Pulmonary Disease PatientsApplication PCTUS2024019769Pending
  • Method Of Treating Enterovirus In Chronic Obstructive Pulmonary Disease PatientsApplication 63578073Pending
  • Method Of Dosing Vapendavir To Treat Enterovirus InfectionsApplication 63578078Pending
  • Method Of Treating Hepatitis C Virus In PatientsApplication 63469153Pending
  • Method Of Dosing Vapendavir To Treat Enterovirus InfectionsApplication 63489936Pending
  • Method Of Treating Enterovirus In Chronic Obstructive Pulmonary Disease PatientsApplication 63489929Pending
  • Pharmaceutical Compositions And Methods Of Treating Enteroviruses With Vapendavir SulfateApplication PCTUS2025042605Pending
  • Method Of Treating Respiratory Conditions In Chronic Obstructive Pulmonary Disease PatientsApplication PCTUS2025042595Pending
  • Method Of Treating Respiratory Conditions In Chronic Obstructive Pulmonary Disease PatientsApplication 63814168Pending
  • Syndax PharmaceuticalsSimilar federal contract value in Biotech · null in contracts
  • Inspirna, Inc.Similar federal contract value in Biotech · null in contracts
  • SATIETY INCSimilar federal contract value in Biotech · null in contracts
  • SOUVIE BIODELIVERY LLCSimilar federal contract value in Biotech · null in contracts
  • VIBE PHARMACEUTICALS LLCSimilar federal contract value in Biotech · null in contracts
  • Zivo Bioscience, Inc.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .